David Silberman
Vermogen: 93 365 $ op 31-05-2026
Vermogen: 93 365 $ op 31-05-2026
David Silberman currently works at Nasus Pharma Ltd., as Director from 2025 and Compugen Ltd., as Chief Financial Officer from 2024.
Mr. Silberman also formerly worked at Teva Pharmaceutical Industries Ltd., as Senior Manager-Global Internal Audit from 2018 to 2021 and Oramed Pharmaceuticals, Inc., as Chief Financial Officer, Secretary & Treasurer from 2021 to 2022.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
COMPUGEN LTD. 0,04% | 18-03-2026 | 35.500 ( 0,04% ) | 93 365 $ | 31-05-2026 |
NASUS PHARMA LTD. -.--% | 25-03-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| COMPUGEN LTD. | Financieel Directeur/CFO | 15-08-2024 |
| NASUS PHARMA LTD. | Directeur/Bestuurslid | 11-08-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
| ORAMED PHARMACEUTICALS INC. | Financieel Directeur/CFO | 09-01-2022 |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Comptroller/Controller/Auditor | 01-05-2021 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
Compugen Ltd.
Compugen Ltd. BiotechnologyHealth Technology Discovers and researches drug & diagnostics | Health Technology |
Oramed Pharmaceuticals, Inc.
Oramed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in pharmaceutical preparations | Health Technology |
Nasus Pharma Ltd.
Nasus Pharma Ltd. Pharmaceuticals: MajorHealth Technology Operates as a drug delivery company that develops powder-based intranasal products | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau